Media coverage about Pharmerica Corporation (NYSE:PMC) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pharmerica Corporation earned a news impact score of 0.06 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.8112350558825 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Pharmerica Corporation (PMC) opened at 29.10 on Friday. The stock has a market capitalization of $905.62 million, a price-to-earnings ratio of 39.43 and a beta of 0.84. Pharmerica Corporation has a 12-month low of $19.20 and a 12-month high of $29.50. The company has a 50-day moving average price of $29.14 and a 200-day moving average price of $26.80.
Pharmerica Corporation (NYSE:PMC) last posted its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.47. The business had revenue of $592.00 million during the quarter, compared to the consensus estimate of $592.96 million. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. Pharmerica Corporation’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.47 earnings per share. On average, equities research analysts forecast that Pharmerica Corporation will post $1.94 earnings per share for the current year.
Several equities research analysts have issued reports on the company. Barrington Research cut Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 9th. KeyCorp lowered Pharmerica Corporation to an “overweight” rating in a research report on Tuesday, August 8th. Zacks Investment Research
upgraded Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Wednesday, September 27th. UBS AG restated a “neutral” rating and set a $29.25 price target (up from $26.00) on shares of Pharmerica Corporation in a research report on Thursday, August 3rd. Finally, BidaskClub lowered Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $30.50.
WARNING: “Pharmerica Corporation (PMC) Given Daily News Sentiment Rating of 0.06” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/27/pharmerica-corporation-pmc-receiving-somewhat-favorable-news-coverage-report-shows.html.
Pharmerica Corporation Company Profile
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.